### ASSET PURCHASE AGREEMENT

by and among

POZEN Inc.,

**Aralez Pharmaceuticals Trading DAC** 

and

Nuvo Pharmaceuticals (Ireland) Limited

Dated as of September 18, 2018



## TABLE OF CONTENTS

| ARTICLE 1 | DEFINITIONS                                  | 2  |
|-----------|--|----|
| 1.1       | Certain Defined Terms.                       | 2  |
| 1.2       | Construction.                                |    |
| ARTICLE 2 | SALE AND PURCHASE OF ASSETS; LIABILITIES     | 18 |
|           |  |    |
| 2.1       | Sale of Purchased Assets.                    |    |
| 2.2       | Liabilities.                                 |    |
| 2.3       | Consideration.                               |    |
| 2.4       | Closing.                                     | 21 |
| ARTICLE 3 | REPRESENTATIONS AND WARRANTIES               | 22 |
| 3.1       | Representations and Warranties of Seller     | 22 |
| 3.2       | Representations and Warranties of Buyer      |    |
| 3.3       | Exclusivity of Representations.              | 29 |
| ARTICLE 4 | PRE-CLOSING COVENANTS                        | 29 |
| 4.1       | Access and Information                       | 29 |
| 4.2       | Ordinary Course of Business.                 |    |
| 4.3       | Notification of Certain Matters.             |    |
| 4.4       | Obligation to Consummate the Transaction     | 32 |
| 4.5       | Financial Statements                         | 32 |
| 4.6       | Non-Solicitation of Bids                     | 33 |
| 4.7       | Key Employee Retention Plan.                 | 33 |
| 4.8       | Financing.                                   |    |
| 4.9       | Co-operation with Financing.                 |    |
| 4.10      | Transitional Services.                       |    |
| 4.11      | Deposit                                      |    |
| 4.12      | TSX Conditional Approval.                    |    |
| 4.13      | Ireland Employees.                           |    |
| 4.14      | Ireland Lease                                | 36 |
| ARTICLE 5 | ADDITIONAL COVENANTS                         | 38 |
| 5.1       | Cooperation in Litigation and Investigations | 38 |
| 5.2       | Further Assurances.                          | 39 |
| 5.3       | Publicity.                                   | 40 |
| 5.4       | Product Liability Claims.                    |    |
| 5.5       | Certain Tax Matters.                         |    |
| 5.6       | Accounts Receivable and Payable.             |    |
| 5.7       | Wrong Pockets.                               |    |
| 5.8       | Purchased Intellectual Property              | 44 |
|           |  |    |



| 5.9        | Bankruptcy Court Filings and Approval                 |    |
|------------|---|----|
| 5.1        | 0   |    |
| 5.1        | **  |    |
| 5.1        | 1 0   |    |
| 5.1        | 3 Patent Enforcement Costs                            | 46 |
| ARTICLE    | 6 CONDITIONS PRECEDENT                                | 46 |
| 6.1        | Conditions to Obligations of Buyer and Seller         | 46 |
| 6.2        | Conditions to Obligations of Buyer                    | 47 |
| 6.3        | Conditions to Obligations of Seller                   | 49 |
| ARTICLE    | 7 NO SURVIVAL OF REPRESENTATIONS, WARRANTIES AND PRE- |    |
|            | CLOSING COVENANTS                                     | 49 |
| 7.1        | No Survival   | 40 |
| 7.1<br>7.2 | No Recourse   |    |
| 1.4        | No Recourse.  | 30 |
| ARTICLE    | 8 TERMINATION   | 50 |
| 8.1        | Termination   |    |
| 8.2        | Procedure and Effect of Termination.                  | 52 |
| 8.3        | Termination Fee; Expense Reimbursement                | 53 |
| ARTICLE    | 9 MISCELLANEOUS                                       | 54 |
| 9.1        | Governing Law, Jurisdiction, Venue and Service        | 54 |
| 9.2        | Notices.  |    |
| 9.3        | No Benefit to Third Parties.                          |    |
| 9.4        | Waiver  |    |
| 9.5        | Expenses  |    |
| 9.6        | Assignment  |    |
| 9.7        | Amendment.  |    |
| 9.8        | Severability  |    |
| 9.9        | Equitable Relief.                                     |    |
| 9.1        | •   |    |
| 9.1        | e e e e e e e e e e e e e e e e e e e                 |    |
| 9.1        | v   |    |
| 9.1        |   |    |
| 9.1        |   |    |
| 9.1        |   |    |
| 9.1        | ±   | 60 |



## 18-12425-mg Doc 412-1 Filed 12/27/18 Entered 12/27/18 12:24:20 Exhibit Asset Purchase Agreement Pg 4 of 240

## **EXHIBITS**

| Exhibit A | Form of Bill of Sale and Assignment and Assumption Agreement |
|-----------|--|
| Exhibit B | Form of Domain Name Transfer Agreement                       |
| Exhibit C | [Intentionally Omitted]                                      |
| Exhibit D | Form of Patent Assignment Agreement                          |
| Exhibit E | Form of Trademark Assignment                                 |
| Exhibit F | Form of Bidding Procedures Order                             |
| Exhibit G | Form of Bid Procedures                                       |
| Exhibit H | Form of Approval Order                                       |
| Exhibit I | Form of Interim DIP Financing Order                          |

ASSET PURCHASE AGREEMENT (this "Agreement") is made and executed as of September 18, 2018 (the "Execution Date"), by and among POZEN Inc., a Delaware corporation ("Pozen"), Aralez Pharmaceuticals Trading DAC, an Irish designated activity company ("Aralez Ireland," and together with Pozen, "Seller") and Nuvo Pharmaceuticals (Ireland) Limited, an Irish corporation ("Buyer"). Seller and Buyer are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

#### RECITALS

WHEREAS, Seller and certain of its Affiliates are engaged in the Product Business;

WHEREAS, on August 10, 2018 (the "Petition Date") Seller and certain of its. Affiliates (the "U.S. Debtors") sought relief under Chapter 11 of Title 11, §§ 101 et seq., of the United States Code (as amended, the "Bankruptcy Code") by filing cases (the "Chapter 11 Cases" and the proceedings commenced by such filing, the "Restructuring Proceedings") in the United States Bankruptcy Court for the Southern District of New York (the "U.S. Bankruptcy Court");

**WHEREAS**, Seller desires to sell to Buyer, and Buyer desires to purchase from Seller, certain assets and rights associated with the Product and the Product Business, upon the terms and conditions hereinafter set forth;

WHEREAS, the Purchased Assets and Assumed Liabilities are assets and liabilities of Seller which are to be sold and assumed pursuant to the Approval Order approving such sale pursuant to section 363 of the Bankruptcy Code, free and clear of all Encumbrances and Liabilities except Assumed Liabilities and Permitted Encumbrances, which order will include the authorization for the assumption and assignment of certain executory contracts and unexpired leases and liabilities thereunder under section 365 of the Bankruptcy Code, all in the manner and subject to the terms and conditions set forth herein and in accordance with other applicable provisions of the Bankruptcy Code;

**WHEREAS**, an Affiliate of Buyer, Nuvo Pharmaceuticals Inc. ("**Nuvo**"), will enter into the Canadian Purchase Agreement (as defined herein) simultaneously with the execution of this Agreement pursuant to which, among other things, Nuvo will agree to purchase all of the shares of Aralez Pharmaceuticals Canada Inc. ("**Aralez Canada**") from an Affiliate of Seller, Aralez Pharmaceuticals Inc. ("**Parent**"), and Parent will agree to sell all of the shares of Aralez Canada to Nuvo;

WHEREAS, in connection with the entry into this Agreement, Buyer shall use commercially reasonable efforts to cause, within five Business Days of the date hereof, an aggregate amount equal to \$1,900,000 in cash to be deposited on its behalf as a "good faith deposit" (the "Deposit") by wire transfer of immediately available funds to the Escrow Agent, to be held in escrow in accordance with the terms of the escrow agreement (the "Deposit Escrow Agreement") entered into on the date hereof between and among Buyer, Seller and the Escrow Agent; and



# DOCKET

## Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

